🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — REDEFINE Phase 3 results Page 3

CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results

Dr.Martinez Sun, Jun 7, 2026 at 10:19 AM 20 replies 606 viewsPage 3 of 4
AussieAnna
Member
678
2,890
Jun 2024
Sydney, AU
Jun 7, 2026 at 2:36 PM#11
Dr.RenalNash said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

Last edited: Jun 7, 2026 at 3:36 PM
28 3TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 25 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Jun 7, 2026 at 5:58 PM#12

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

27 2FranDenver, Dr.BariatricHTX, LindaRN_retired and 24 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Jun 7, 2026 at 9:21 PM#13
Dr.SurgeonPGH said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: Jun 8, 2026 at 12:21 AM
26 1Admin, Dr.Martinez, mike_mod and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Jun 8, 2026 at 12:43 AM#14

One concrete data point for the thread. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

25 0andrew_nyc, Dr.EndoEP, GraceAZ_72 and 22 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 4:05 AM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. No action needed from anybody.

24 24PurityPaulOR, MaxMetOK, MounjBrad and 21 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
Survodutide (GCG/GLP-1) — MASH and obesity trial results16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register